newsfilter
← Earnings
Earnings Releases·

Silexion Therapeutics — Third Quarter 2026 Earnings Summary

Silexion Therapeutics dosed the first patient in its Phase 2/3 clinical trial for SIL204 in locally advanced pancreatic cancer at Tel Aviv Sourasky Medical Center in September 2026. The company reported a net loss of $2.5 million for the third quarter of 2026, while cash and cash equivalents increased to $4.8 million following recent financing activities. New translational data indicates that SIL204 utilizes a coordinated immune-sensitization signature across four KRAS mutations and employs a native lipoprotein-mediated uptake mechanism. Additionally, the company announced a 1-for-24 reverse share split effective November 10, 2026, and is expanding clinical trial sites in Israel and Germany.

Company
SILEXION THERAPEUTICS CORP
Sector
Healthcare
Industry
Biotechnology